Kaiyue

Shenzhen Kaiyue Life Technology (also known as KeYe Life Technologies) is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule drugs for oncology. The company's lead program, KY-386, is a first-in-class small molecule inhibitor of the RNA helicase DHX33, which has been identified as a critical driver of tumorigenesis and a regulator of the mevalonate pathway and lipid metabolism. KY-386 exerts its anticancer effects by inducing ferroptosis and apoptosis in cancer cells while showing minimal toxicity to normal cells. The company is advancing a pipeline of DHX33 inhibitors and other small molecules to treat a broad range of solid tumors and hematological malignancies. Founded in 2016, the company leverages its expertise in RNA helicase biology to address unmet medical needs in cancer treatment.